Pharmaceutical major Lupin Ltd. has entered into a strategic license and supply agreement with Costa Rica-based SteinCares to commercialize its biosimilar ranibizumab in Latin America, excluding Mexico and Argentina. Under this collaboration, SteinCares will lead regulatory filings and distribution, while Lupin will retain responsibility for manufacturing. The move aligns with Lupin’s broader vision of increasing access to advanced biologic therapies in emerging markets.